abstract |
A pharmaceutical composition for preventing or treating diseases or disorders characterized by chronic inflammation associated with angiogenesis and fibrosis. The pharmaceutical composition includes a multi-target inhibitor, a multi-phase modulator or a multi-kinase inhibitor, such as axitinib, nintedanib, pirfenidone, lioxidia, sorafenib, sunitin Ni, levatinib, regorafenib, panatinib, or pazopanib. |